Home
Pipeline&Products
Science&Innovation
Recombinant IgG Cleaving Enzyme
Recombinant Human Hyaluronidase
Solutions
Investor Relations
Media
About Us
Our Stories
Join Us
Contact Us
简
EN
繁
Home
Pipeline&Products
Science&Innovation
Recombinant IgG Cleaving Enzyme
Recombinant Human Hyaluronidase
Solutions
Investor Relations
Media
About Us
Our Stories
Join Us
Contact Us
简
EN
繁
Please enter the information you want to find
Hot key words:
Hyaluronidase
xxx
News Center
All
2025.12.10
Shanghai Bao Pharma Successfully Listed on the Hong Kong Stock Exchange, Ushering in a New Era of Recombinant Biologics
View details
2026.06.22
Breaking the 600-day mark! Baoji sets new Asian records in cross-species kidney transplants
View details
2026.06.04
China’s First Filing! Bao Pharma’s IgG-Degrading Enzyme KJ103 NDA Accepted by China’s NMPA and Granted Priority Review
View details
2026.05.14
Bao Pharmaceutical Included in the MSCI Global Index Constituents, with Its Innovative R&D Strength Recognised Globally
View details
2026.04.17
Bao Pharma’s Recombinant Ulinastatin (BJ044) IND Accepted, Marking a New Era for Recombinant Protein Therapeutics
View details
1
2
3
4
5